Molecular and Clinicopathologic Impact of GNAS Variants Across Solid Tumors

Scientists assessed 58,043 patients with Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets–sequenced solid tumors to identify oncogenic variants, including GNAS, associated with mucinous tumor phenotype.